The study is designed to determine the safety and efficacy of progesterone in patients with severe head injury
- Conditions
- Severe traumatic brain injuryTherapeutic area: Diseases [C] - Nervous System Diseases [C10]MedDRA version: 16.0 Level: LLT Classification code 10060690 Term: Traumatic brain injury System Organ Class: 100000004863
- Registration Number
- EUCTR2010-018283-16-GB
- Lead Sponsor
- BHR Pharma, LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 1180
1.Male or female patients, age between 16 and 70 years, inclusive (or lower age limit as required by local regulations)
2.Weight from 45 to 135 kg, inclusive.
3.Sustained a closed head trauma no more than 8 hours before initiation of study drug infusion (exposed dura mater is acceptable in the case of depressed skull fractures)
4.TBI diagnosed by history and clinical examination
5.Post-resuscitation GCS score between 3 and 8, inclusive
6.At least one reactive pupil (pinpoint pupils due to opioid pain treatment are considered reactive)
7.Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (Diffuse injury II-IV, evacuated and non-evacuated mass lesion, Marshall’s CT Classification)
8.Indication for ICP monitoring
Are the trial subjects under 18? yes
Number of subjects for this age range: 23
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1062
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 95
1.Life expectancy of less than 24 hours as determined by the Investigator
2.Prolonged and/or uncorrectable hypoxia (Pa02< 60 mmHg) or hypotension (systolic blood pressure < 90 mmHg) at the time of randomization
3.Any spinal cord injury
4.Pregnancy
5.Penetrating head injury
6.Bilaterally fixed dilated pupils at the time of randomization
7.Coma suspected to be primarily due to other causes (e.g. alcohol)
8.Pure epidural hematoma
9.Preexisting clinically significant disease or chronic condition that can be ascertained at the time of admission and could affect functional outcome
10.Severe cardiac or hemodynamic instability after resuscitation prior to randomization
11.Known treatment with another investigational drug, device, medical therapy or procedure within 30 days of injury.
12.A history of allergic reaction to progesterone and related drugs or any of the components of the infusion
13.Any disease, in the opinion of the Investigator, that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
14.Subjects who, in the opinion of the Investigator, would not be able or willing to comply with the protocol through the final visit ( 6 months post-injury)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method